Capvizr
THE DEAL, AT A GLANCE

Star Therapeutics

From the announcement
01
MoleculesDrug research
Medicine development
What it doesStar Therapeutics is a Digital Health company focused on advance its lead program, VGA039, for treating bleeding disorders.From the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗
02Who is involvedBacked by the sharpest minds in the pharmaceutical, biotechnology space for a weekFrom the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗
03What happenedStar Therapeutics raised $125M Series D, announced 2025-09-30From the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗
04Why it mattersStar Therapeutics' $125M Series D is a capital-flow signal within Healthcare & Life Sciences, positioned above the midpoint of tracked sector rounds at the 68th…From the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗
Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗

Star Therapeutics · Financing Record

Explore source-linked visual explanations for Star Therapeutics. Unsupported claims are withheld while source review continues.

Record 2853 · Recorded date: 2025-09-30

Explore company records →
Free weekday briefing

Know which funding rounds matter before the first call.

Source-linked rounds, lead investors, and the signal behind the capital. One five-minute read.

Free · Unsubscribe anytime